AstraZeneca is raising concerns that a manufacturing site could be relocated to France, putting an investment in jeopardy.

Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch r...

COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The ...

Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare d...

A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monothera...

TD Cowen analyst Steve Scala maintains AstraZeneca (NASDAQ:AZN) with a Buy and raises the price target from $90 to $95.

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments ...

The Bank of England cuts interest rate for first time in over 4 years to 5%, citing inflation below target and emerging economi...

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact fro...